$OVID Cashflow Statement | Understand Stock

$OVID

$2.26 +$0.10 (4.87%) Close

$OVID Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Non-cash research and development expense
Non-cash consideration received in licensing agreement transaction
Change in fair value of royalty monetization liability
Unrealized gain on equity investments
Interest income and accretion of discount on marketable securities
Change in accrued interest and accretion of discount on marketable securities
Stock-based compensation expense
Depreciation and amortization expense
Change in accrued interest and accretion of discount on short-term investments
Noncash operating lease expense
Accretion of lease liability
Change in lease liability
Change in operating assets and liabilities:
Prepaid expenses and other current assets
Security deposit
Accounts payable
Accrued expenses
Deferred revenue
Related party payable
Related party receivable
Long-term prepaid expenses

Net cash used in operating activities
Cash flows from investing activities:
Purchase of marketable securities
Proceeds from maturities of short-term investments
Sales/maturities of marketable securities
Purchase of long-term equity investment
Issuance of convertible short-term note receivable
Purchases of property and equipment
Software development and other costs
Net cash (used in) provided by investing activities

Cash flows from financing activities:
Proceeds from August 2020 Offering, net of offering expenses
ATM and other offering costs
Proceeds from employee stock purchase plan
Proceeds from private placement financing, net of transaction costs
Proceeds from exercise of options and employee stock purchase plan
Proceeds from royalty monetization agreement
Net cash provided by financing activities

Effect of exchange rates on cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, at beginning of period
Cash, cash equivalents and restricted cash, at end of period
Software development and other costs in accrued expenses and accounts payable
Offering costs in accrued expenses and accounts payable
Right-of-use asset in exchange for lease liability
Conversion of short-term note receivable to long-term equity investment

Comments